Author:
Harford P S,Murray B E,DuPont H L,Ericsson C D
Abstract
During a therapeutic trial of bicozamycin (BI) for traveler's diarrhea, aerobically grown, gram-negative bacteria, predominantly Escherichia coli, were decreased by 2 to 3 logs per g of stool; the number of BI-resistant gram-negative bacteria did not increase. Resistant species were most often Citrobacter freundii, Klebsiella pneumoniae, and Morganella morganii, and few BI-resistant E. coli strains were isolated. Cross-resistance between BI and other antimicrobial agents was not found. Resistance to BI could not be transferred or mobilized to an E. coli K-12 recipient.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference9 articles.
1. Bicyclomycin, a new antibiotic. II. Structural elucidation and acyl derivatives;Kamiya T.;J. Antibiot. (Tokyo),1972
2. Bicyclomycin, a new antibiotic. I. Taxonomy, isolation, and characterization;Miyoshi T.;J. Antibiot.,1972
3. Aminoglycoside-modifying enzymes among clinical isolates of Acinetobacter calcoaceticus subsp. anitratus (Herellea vaginicola): explanation for high-level aminoglycoside resistance;Murray B. E.;Antimicrob. Agents Chemother.,1978
4. Emergence of high level trimethoprim resistance in fecal Escherichia coli during oral administration of trimethoprim or trimethoprim/sulfamethoxazole;Murray B. E.;N. Engl. J. Med.,1982
5. Bicyclomycin, a new antibiotic. III. In vitro and in vivo antimicrobial activity;Niahida M.;J. Antibiot.,1972
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献